Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2016 -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a biopharmaceutical company developing novel treatments for nonalcoholic steatohepatitis (NASH), and other serious immuno-inflammatory and fibrotic diseases, will report financial results for the quarter ended December 31, 2015 after market close on Thursday March 3, 2016. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Date: March 3, 2016
Time: 1:30 PM PT
Listen via Internet: http://ir.tobiratherapeutics.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=71315&k=7CAD412C
Toll-free: 1 (855) 638-8858
International: +1 (707) 294-1299
Password: 47016109
A webcast replay will be available on the Tobira Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 47016109.
About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Learn more about Tobira at www.tobiratherapeutics.com.
CONTACT: Tobira Investor & Media Contact
Ian Clements, PhD
+1 (650) 351-5013
[email protected]
Canale Communications Media Contact
Pam Lord
+1 (619) 849-6003
[email protected]
